These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 37227299)
1. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Kissling E; Maurel M; Emborg HD; Whitaker H; McMenamin J; Howard J; Trebbien R; Watson C; Findlay B; Pozo F; Bolt Botnen A; Harvey C; Rose A; ; Euro Surveill; 2023 May; 28(21):. PubMed ID: 37227299 [TBL] [Abstract][Full Text] [Related]
2. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Rose A; Kissling E; Emborg HD; Larrauri A; McMenamin J; Pozo F; Trebbien R; Mazagatos C; Whitaker H; Valenciano M; Euro Surveill; 2020 Mar; 25(10):. PubMed ID: 32183932 [TBL] [Abstract][Full Text] [Related]
3. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F; Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723 [TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A; Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024 [TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Maurel M; Pozo F; Pérez-Gimeno G; Buda S; Sève N; Oroszi B; Hooiveld M; Gomez V; Domegan L; Martínez-Baz I; Ilić M; Carnahan AS; Mihai ME; Martínez A; Goerlitz L; Enouf V; Horváth JK; Dijkstra F; Rodrigues AP; Bennett C; Trobajo-Sanmartín C; Mlinarić I; Latorre-Margalef N; Ivanciuc A; Lopez A; Dürrwald R; Falchi A; Túri G; Meijer A; Melo A; O'Donnell J; Castilla J; Vučina VV; Hagey TS; Lazar M; Kaczmarek M; Bacci S; Kissling E; Influenza Other Respir Viruses; 2024 Jan; 18(1):e13243. PubMed ID: 38204584 [TBL] [Abstract][Full Text] [Related]
6. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Kissling E; Rose A; Emborg HD; Gherasim A; Pebody R; Pozo F; Trebbien R; Mazagatos C; Whitaker H; Valenciano M; Euro Surveill; 2019 Feb; 24(8):. PubMed ID: 30808440 [TBL] [Abstract][Full Text] [Related]
7. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. Kissling E; Pozo F; Martínez-Baz I; Buda S; Vilcu AM; Domegan L; Mazagatos C; Dijkstra F; Latorre-Margalef N; Kurečić Filipović S; Machado A; Lazar M; Casado I; Dürrwald R; van der Werf S; O'Donnell J; Linares Dopido JA; Meijer A; Riess M; Višekruna Vučina V; Rodrigues AP; Mihai ME; Castilla J; Goerlitz L; Falchi A; Connell J; Castrillejo D; Hooiveld M; Carnahan A; Ilić M; Guiomar R; Ivanciuc A; Maurel M; Omokanye A; Valenciano M; Influenza Other Respir Viruses; 2023 Jan; 17(1):e13069. PubMed ID: 36702797 [TBL] [Abstract][Full Text] [Related]
8. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Kissling E; Valenciano M; Pozo F; Vilcu AM; Reuss A; Rizzo C; Larrauri A; Horváth JK; Brytting M; Domegan L; Korczyńska M; Meijer A; Machado A; Ivanciuc A; Višekruna Vučina V; van der Werf S; Schweiger B; Bella A; Gherasim A; Ferenczi A; Zakikhany K; O Donnell J; Paradowska-Stankiewicz I; Dijkstra F; Guiomar R; Lazar M; Kurečić Filipović S; Johansen K; Moren A; Influenza Other Respir Viruses; 2018 Jul; 12(4):423-437. PubMed ID: 29125681 [TBL] [Abstract][Full Text] [Related]
9. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada. Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166 [TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Kissling E; Valenciano M; Buchholz U; Larrauri A; Cohen JM; Nunes B; Rogalska J; Pitigoi D; Paradowska-Stankiewicz I; Reuss A; Jiménez-Jorge S; Daviaud I; Guiomar R; O'Donnell J; Necula G; Głuchowska M; Moren A Euro Surveill; 2014 Feb; 19(6):. PubMed ID: 24556348 [TBL] [Abstract][Full Text] [Related]
11. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. Chung JR; Kim SS; Kondor RJ; Smith C; Budd AP; Tartof SY; Florea A; Talbot HK; Grijalva CG; Wernli KJ; Phillips CH; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Reis M; Geffel KM; Nowalk MP; DaSilva J; Keong LM; Stark TJ; Barnes JR; Wentworth DE; Brammer L; Burns E; Fry AM; Patel MM; Flannery B MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):365-370. PubMed ID: 35271561 [TBL] [Abstract][Full Text] [Related]
12. Estimation of the Effectiveness of Quadrivalent Influenza Vaccines by Distinguishing Between Influenza A (H1N1) pdm09 and Influenza A (H3N2) Using Rapid Influenza Diagnostic Tests During the 2018-2019 Season. Ando S Intern Med; 2020 Apr; 59(7):933-940. PubMed ID: 31787695 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Andrews N; McMenamin J; Durnall H; Ellis J; Lackenby A; Robertson C; von Wissmann B; Cottrell S; Smyth B; Moore C; Gunson R; Zambon M; Fleming D; Pebody R Euro Surveill; 2014 Jul; 19(27):5-13. PubMed ID: 25033051 [TBL] [Abstract][Full Text] [Related]
14. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Maurel M; Howard J; Kissling E; Pozo F; Pérez-Gimeno G; Buda S; Sève N; McKenna A; Meijer A; Rodrigues AP; Martínez-Baz I; Mlinarić I; Latorre-Margalef N; Túri G; Lazăr M; Mazagatos C; Echeverria A; Abela S; Bourgeois M; Machado A; Dürrwald R; Petrović G; Oroszi B; Jancoriene L; Marin A; Husa P; Duffy R; Dijkstra F; Gallardo García V; Goerlitz L; Enouf V; Bennett C; Hooiveld M; Guiomar R; Trobajo-Sanmartín C; Višekruna Vučina V; Samuelsson Hagey T; Lameiras Azevedo AS; Castilla J; Xuereb G; Delaere B; Gómez V; Tolksdorf K; Bacci S; Nicolay N; Kaczmarek M; Rose AM; Euro Surveill; 2024 Feb; 29(8):. PubMed ID: 38390651 [TBL] [Abstract][Full Text] [Related]
15. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine. McLean HQ; Caspard H; Griffin MR; Gaglani M; Peters TR; Poehling KA; Ambrose CS; Belongia EA JAMA Netw Open; 2018 Oct; 1(6):e183742. PubMed ID: 30646262 [TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Rose AMC; Pozo F; Martínez-Baz I; Mazagatos C; Bossuyt N; Cauchi JP; Petrović G; Loghin II; Vaikutyte R; Buda S; Machado A; Duffy R; Oroszi B; Howard J; Echeverria A; Andreu C; Barbezange C; Džiugytė A; Nonković D; Popescu CP; Majauskaite F; Tolksdorf K; Gomez V; Domegan L; Horváth JK; Castilla J; García M; Demuyser T; Borg ML; Tabain I; Lazar M; Kubiliute I; Dürrwald R; Guiomar R; O'Donnell J; Kristóf K; Nicolay N; Bacci S; Kissling E; ; Influenza Other Respir Viruses; 2024 Feb; 18(2):e13255. PubMed ID: 38403302 [TBL] [Abstract][Full Text] [Related]
17. A late sharp increase in influenza detections and low interim vaccine effectiveness against the circulating A(H3N2) strain, Denmark, 2021/22 influenza season up to 25 March 2022. Emborg HD; Vestergaard LS; Botnen AB; Nielsen J; Krause TG; Trebbien R Euro Surveill; 2022 Apr; 27(15):. PubMed ID: 35426361 [TBL] [Abstract][Full Text] [Related]
18. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. Dawood FS; Chung JR; Kim SS; Zimmerman RK; Nowalk MP; Jackson ML; Jackson LA; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Dunnigan K; Foust A; Sessions W; DaSilva J; Le S; Stark T; Kondor RJ; Barnes JR; Wentworth DE; Brammer L; Fry AM; Patel MM; Flannery B MMWR Morb Mortal Wkly Rep; 2020 Feb; 69(7):177-182. PubMed ID: 32078591 [TBL] [Abstract][Full Text] [Related]
19. Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019. Mouratidou E; Lambrou A; Andreopoulou A; Gioula G; Exindari M; Kossyvakis A; Pogka V; Mentis A; Georgakopoulou T; Lytras T Vaccine; 2020 Mar; 38(12):2715-2724. PubMed ID: 32033848 [TBL] [Abstract][Full Text] [Related]
20. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season. Wu S; Pan Y; Zhang X; Zhang L; Duan W; Ma C; Zhang Y; Zhang M; Sun Y; Yang P; Wang Q; Ma J Vaccine; 2018 Sep; 36(38):5774-5780. PubMed ID: 30087046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]